Tuberculosis vaccine
Publications:
Nascimento IP, Rodriguez D, Santos CC, Amaral EP, Rofatto HK, Junqueira-Kipnis AP, Gonçalves EDC, D'Império-Lima MR, Hirata MH, Silva CL, Winter N, Gicquel B, Mills KHG, Pizza M, Rappuoli R, Leite LCC. Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis. Sci Rep. 2017, 7(1): 2109. doi: 10.1038/s41598-017-02003-9.
Santos, CC, Rodriguez, D, Kanno AI , Leite, LCC & Nascimento, IP (2019): Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria, Hum Vaccin Immunother. 2020;16(3):673-683. doi:10.1080/21645515.2019.1669414.
Marques-Neto LM, Piwowarska Z, Kanno Al, Moraes L, Trentini MM, Rodriguez D, Silva JLSC, Leite LCC. Thirty years of recombinant BCG: new trends for a centenary vaccine. Expert Rev Vaccines. 2021 Jul 13:1 -11. doi: 10.1080/14760584.2021 . 1951243.
dos Santos, C.C.; Walburg, K.V.; van Veen, S.; Wilson, L.G.; Trufen, C.E.M.; Nascimento, I.P.; Ottenhoff, T.H.M.; Leite, L.C.C.; Hacks, M.C. Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces and Inflammatory Profile in Human Macrophages. Vaccines 2022, 10, 831. http://doi.org/10.3390/vaccines10060831.
Moraes L, Trentini MM, Fousteris D, Eto SF, Chudzinski-Tavassi AM, Leite LCC, Kanno AI. CRISPR/Cas9 Approach to Generate na Auxotrophic BCG Strain for Unmarked Expression of LTAK63 Adjuvant: A Tuberculosis Vaccine Candidate. Front Immunol. 2022. Mar 30; 13:867195. doi: 10.3389/fimmu.2022.867195.
Marques-Neto LM, Trentini MM, Kanno AI, Rodriguez D, Leite LCC. Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice. Front Immunol. 2023 Jul 13; 14:1205449. doi: 10.3389/fimmu.2023.1205449.
Patents under negotiation with Butantan
1 – Leite, LCC, Nascimento, IP “Cepa de Mycobacterium bovis, Bacilus Calmette Guerin (BCG), Recombinante, composição imunogênica e uso” process INPI nº 020120037904, Fevereiro 17, 2012. Situação: Pendente.
PCT to different countries:
1.1 – Leite, LCC, Nascimento, IP “Recombinant strain of Mycobacterium bovis Bacilus Guerin (BCG), immunogenic composition and use” United States Patent No.: US 9,512,186 B2 Date Dec 6, 2016.
1.2 – Leite, LCC, Nascimento, IP “Recombinant strain of Mycobacterium bovis Bacilus Guerin (BCG), immunogenic composition and use” Republic of South Africa Patent Office No.: 2014/06437 Date Mar 30, 2016.
1.3 – Leite, LCC, Nascimento, IP “Recombinant strain of Mycobacterium bovis Bacilus Guerin (BCG), immunogenic composition and use” China Patent Office No.: 2014/06437 Date Feb 27, 2018.
1.4 – Leite, LCC, Nascimento, IP “Recombinant strain of Mycobacterium bovis Bacilus Guerin (BCG), immunogenic composition and use” Europe Patent Office No.: 2816106 Date Oct 10, 2021.
2 – Kanno, AI, Moraes, L, Leite, LCC. “Processo para construção de um único vetor compreendendo Cas9 e sgRNA para modificações do genoma de micobactérias”, INPI Processo no BR 10 2020 026128 2, dezembro 18, 2020, Situação: Pendente.
3 – Leite, LCC, Moreno, ACR, Soto, DCR, Trentini, MM. “Composições compreendendo cepas de Mycobaterium recombinantes, respectivos usus e métodos para prevenção e/ou tratamento de câncer”. INPI Processo BR 10 2022 002660 2, fevereiro 11, 2022. Situação: Pendente.
4 – Borban, LS, Batista, RD, Leite, LCC, Gonçalves, VM, “Processo de cultivo submerse de Mycobacterium bovis de crescimento lento, Bacilo Calmette-Guérin ou suas formas recombinants em biorreator e seu uso” INPI Proc No BR 10 2023 004683 5, março 14, 2023. Situação: Pendente.